 |
Market Focus
|
|
QLT is focused on the development and commercialization of innovative therapeutics that address unmet medical needs for ocular diseases.
AMD
Age-related macular degeneration (AMD) is the major cause of vision loss in people over the age of 55. Over the next 20 years, as the population ages, the number of wet AMD cases is estimated to grow by 50%, according to the Eye Disease Prevalence Research Group. Affecting mainly Caucasians, this trend is creating a serious public health concern. Currently there are 500,000 new cases of wet AMD diagnosed each year worldwide.
For more information on our AMD product, click here.
Glaucoma
Glaucoma affects 65 million people worldwide and the total US market is about $1.7 billion. It is the second leading cause of blindness and the majority of glaucoma patients are treated with topical medications requiring visits to ophthalmologists per year. Despite the importance of treatment, patients are notoriously non-compliant due in part to the complexity of the current treatment regimens which include a variety of eye drops.
For more information on our punctal plug technology, click here. |
|
| |
|
|
|
|
|
|
|
|
